The iron deficiency anemia therapy market size has grown strongly in recent years. It will grow from $4.46 billion in 2024 to $4.82 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to several factors, including increased research and development, the introduction of novel drugs, advancements in iron supplementation, the rising prevalence of iron deficiency anemia, a stronger focus on social healthcare, and improvements in available treatment options.
The iron deficiency anemia therapy market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The projected growth in the forecast period can be attributed to several factors, including increased promotional activities, awareness campaigns, the expansion of specialized medicine pipelines, rising nutritional deficiencies and dietary changes, a broader range of iron-based therapy options, and the growing incidence of maternal iron deficiency. Key trends to watch during this period include the development of iron-targeting nanotechnology, wearable health monitors, smart iron supplements, blood iron biosensors, and nanorobots designed for targeted iron delivery.
The growing prevalence of chronic diseases is expected to significantly fuel the growth of the iron deficiency anemia therapy market in the coming years. Chronic diseases are long-term medical conditions that typically last for a year or more. The rise in these diseases can be attributed to unhealthy lifestyle factors, such as poor diet, lack of physical activity, and smoking, which contribute to conditions including obesity, diabetes, and heart disease. These chronic conditions can hinder the body’s ability to absorb iron properly, increasing the risk of iron deficiency and thereby creating a greater need for supplementation and therapy to restore iron levels. For example, in June 2024, the National Health Service (NHS) of the United Kingdom reported that 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia (pre-diabetes) in 2023, representing an 18% increase from the 3,065,825 cases recorded in 2022. As the number of chronic disease cases rises, the demand for iron deficiency anemia therapy continues to grow.
Leading companies in the iron deficiency anemia therapy market are increasingly focused on advancing treatment options, such as injectable formulations, to improve efficacy and accessibility. Injectable formulations are newly developed or modified drug versions administered via injection, offering a more effective and convenient approach compared to traditional oral supplements. For example, in May 2023, Emcure Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Orofer FCM 750, a ferric carboxymaltose (FCM) formulation designed to treat iron deficiency and iron deficiency anemia (IDA). The benefits of this formulation include improved patient compliance due to less frequent administration compared to oral supplements. Orofer FCM 750 is a 750 mg/15 ml injectable that has been approved by India’s DCGI for treating IDA in patients who are unresponsive to oral iron, particularly for pregnant women with hemoglobin levels below 10 g/dL and a weight range of 35-70 kg. It provides a 15-minute infusion when diluted in saline, aligning with Anemia Mukt Bharat guidelines as a first-line treatment for severe cases.
In August 2022, CSL Limited, an Australia-based biotechnology company specializing in iron deficiency injectables, acquired Vifor Pharma for an undisclosed amount. This acquisition strengthens CSL's commitment to patient care and enhances its capacity to offer innovative treatments. Vifor Pharma Ltd. is a Switzerland-based pharmaceutical company, focusing on providing therapies for iron deficiency and iron deficiency anemia.
Major players in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Akebia Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., Ironic Biotech AB, KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, and Shield Therapeutics plc.
North America was the largest region in the iron deficiency anemia therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron deficiency anemia therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the iron deficiency anemia therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Iron deficiency anemia therapy involves a comprehensive approach focused on restoring iron levels in the body to support normal red blood cell production. The primary objective is to treat the root cause of the iron deficiency, which may include changes in diet, iron supplementation, or medical treatment when necessary.
Key product types used in this therapy include ferrous sulfate, ferrous gluconate, ferrous fumarate, and ferric hydroxide. Ferrous sulfate is one of the most widely used supplements for treating iron deficiency anemia. These products are utilized across different therapy types such as oral iron therapy, parenteral iron therapy, red blood cell transfusions, and more. The therapy is applied in multiple medical areas including inflammatory bowel diseases, renal disorders, obstetrics and gynecology, congestive heart failure, and oncology. Distribution takes place through hospital pharmacies, retail pharmacies, drug stores, and online platforms. The end users of these therapies include hospitals, specialty clinics, home care settings, and other healthcare providers.
The iron deficiency anemia therapy market research report is one of a series of new reports that provides iron deficiency anemia therapy market statistics, including iron deficiency anemia therapy industry global market size, regional shares, competitors with a iron deficiency anemia therapy market share, iron deficiency anemia therapy market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia therapy industry. This iron deficiency anemia therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The iron deficiency anemia therapy market consists of revenues earned by entities by providing services such as iron supplementation, diagnostic services, nutritional counseling, home healthcare services, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia therapy market also includes sales of oral iron supplements, intravenous (IV) iron preparations, erythropoiesis-stimulating agents, iron-fortified foods, and blood transfusion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The iron deficiency anemia therapy market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The projected growth in the forecast period can be attributed to several factors, including increased promotional activities, awareness campaigns, the expansion of specialized medicine pipelines, rising nutritional deficiencies and dietary changes, a broader range of iron-based therapy options, and the growing incidence of maternal iron deficiency. Key trends to watch during this period include the development of iron-targeting nanotechnology, wearable health monitors, smart iron supplements, blood iron biosensors, and nanorobots designed for targeted iron delivery.
The growing prevalence of chronic diseases is expected to significantly fuel the growth of the iron deficiency anemia therapy market in the coming years. Chronic diseases are long-term medical conditions that typically last for a year or more. The rise in these diseases can be attributed to unhealthy lifestyle factors, such as poor diet, lack of physical activity, and smoking, which contribute to conditions including obesity, diabetes, and heart disease. These chronic conditions can hinder the body’s ability to absorb iron properly, increasing the risk of iron deficiency and thereby creating a greater need for supplementation and therapy to restore iron levels. For example, in June 2024, the National Health Service (NHS) of the United Kingdom reported that 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia (pre-diabetes) in 2023, representing an 18% increase from the 3,065,825 cases recorded in 2022. As the number of chronic disease cases rises, the demand for iron deficiency anemia therapy continues to grow.
Leading companies in the iron deficiency anemia therapy market are increasingly focused on advancing treatment options, such as injectable formulations, to improve efficacy and accessibility. Injectable formulations are newly developed or modified drug versions administered via injection, offering a more effective and convenient approach compared to traditional oral supplements. For example, in May 2023, Emcure Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Orofer FCM 750, a ferric carboxymaltose (FCM) formulation designed to treat iron deficiency and iron deficiency anemia (IDA). The benefits of this formulation include improved patient compliance due to less frequent administration compared to oral supplements. Orofer FCM 750 is a 750 mg/15 ml injectable that has been approved by India’s DCGI for treating IDA in patients who are unresponsive to oral iron, particularly for pregnant women with hemoglobin levels below 10 g/dL and a weight range of 35-70 kg. It provides a 15-minute infusion when diluted in saline, aligning with Anemia Mukt Bharat guidelines as a first-line treatment for severe cases.
In August 2022, CSL Limited, an Australia-based biotechnology company specializing in iron deficiency injectables, acquired Vifor Pharma for an undisclosed amount. This acquisition strengthens CSL's commitment to patient care and enhances its capacity to offer innovative treatments. Vifor Pharma Ltd. is a Switzerland-based pharmaceutical company, focusing on providing therapies for iron deficiency and iron deficiency anemia.
Major players in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Akebia Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., Ironic Biotech AB, KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, and Shield Therapeutics plc.
North America was the largest region in the iron deficiency anemia therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in iron deficiency anemia therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the iron deficiency anemia therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Iron deficiency anemia therapy involves a comprehensive approach focused on restoring iron levels in the body to support normal red blood cell production. The primary objective is to treat the root cause of the iron deficiency, which may include changes in diet, iron supplementation, or medical treatment when necessary.
Key product types used in this therapy include ferrous sulfate, ferrous gluconate, ferrous fumarate, and ferric hydroxide. Ferrous sulfate is one of the most widely used supplements for treating iron deficiency anemia. These products are utilized across different therapy types such as oral iron therapy, parenteral iron therapy, red blood cell transfusions, and more. The therapy is applied in multiple medical areas including inflammatory bowel diseases, renal disorders, obstetrics and gynecology, congestive heart failure, and oncology. Distribution takes place through hospital pharmacies, retail pharmacies, drug stores, and online platforms. The end users of these therapies include hospitals, specialty clinics, home care settings, and other healthcare providers.
The iron deficiency anemia therapy market research report is one of a series of new reports that provides iron deficiency anemia therapy market statistics, including iron deficiency anemia therapy industry global market size, regional shares, competitors with a iron deficiency anemia therapy market share, iron deficiency anemia therapy market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia therapy industry. This iron deficiency anemia therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The iron deficiency anemia therapy market consists of revenues earned by entities by providing services such as iron supplementation, diagnostic services, nutritional counseling, home healthcare services, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The iron deficiency anemia therapy market also includes sales of oral iron supplements, intravenous (IV) iron preparations, erythropoiesis-stimulating agents, iron-fortified foods, and blood transfusion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Iron Deficiency Anemia Therapy Market Characteristics3. Iron Deficiency Anemia Therapy Market Trends And Strategies4. Iron Deficiency Anemia Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Iron Deficiency Anemia Therapy Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Iron Deficiency Anemia Therapy Market34. Recent Developments In The Iron Deficiency Anemia Therapy Market
5. Global Iron Deficiency Anemia Therapy Growth Analysis And Strategic Analysis Framework
6. Iron Deficiency Anemia Therapy Market Segmentation
7. Iron Deficiency Anemia Therapy Market Regional And Country Analysis
8. Asia-Pacific Iron Deficiency Anemia Therapy Market
9. China Iron Deficiency Anemia Therapy Market
10. India Iron Deficiency Anemia Therapy Market
11. Japan Iron Deficiency Anemia Therapy Market
12. Australia Iron Deficiency Anemia Therapy Market
13. Indonesia Iron Deficiency Anemia Therapy Market
14. South Korea Iron Deficiency Anemia Therapy Market
15. Western Europe Iron Deficiency Anemia Therapy Market
16. UK Iron Deficiency Anemia Therapy Market
17. Germany Iron Deficiency Anemia Therapy Market
18. France Iron Deficiency Anemia Therapy Market
19. Italy Iron Deficiency Anemia Therapy Market
20. Spain Iron Deficiency Anemia Therapy Market
21. Eastern Europe Iron Deficiency Anemia Therapy Market
22. Russia Iron Deficiency Anemia Therapy Market
23. North America Iron Deficiency Anemia Therapy Market
24. USA Iron Deficiency Anemia Therapy Market
25. Canada Iron Deficiency Anemia Therapy Market
26. South America Iron Deficiency Anemia Therapy Market
27. Brazil Iron Deficiency Anemia Therapy Market
28. Middle East Iron Deficiency Anemia Therapy Market
29. Africa Iron Deficiency Anemia Therapy Market
30. Iron Deficiency Anemia Therapy Market Competitive Landscape And Company Profiles
31. Iron Deficiency Anemia Therapy Market Other Major And Innovative Companies
35. Iron Deficiency Anemia Therapy Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Iron Deficiency Anemia Therapy Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on iron deficiency anemia therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for iron deficiency anemia therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iron deficiency anemia therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product Type: Ferrous Sulphate; Ferrous Gluconate; Ferrous Fumerate; Ferric Hydroxide2) By Therapy Type: Parenteral Iron Therapy; Oral Iron Therapy; Red Blood Cell Transfusion; Other Therapy Types
3) By Therapy Areas: Inflammatory Bowel Diseases; Renal Diseases; Obstetrics and Gynecology; Congestive Heart Failure; Oncology
4) By Distribution channel: Hospital Pharmacy; Drug Stores And Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Speciality Clinics; Home Care Setting; Other End Users
Subsegments:
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets; Oral Liquid Ferrous Sulphate; Intravenous Ferrous Sulphate; Extended Or Delayed Release Formulations2) By Ferrous Gluconate: Oral Tablets; Chewable Tablets; Liquid Solutions; Pediatric Formulations
3) By Ferrous Fumarate: Oral Tablets Or Capsules; Prenatal Supplements; Multivitamin with Iron Formulations; Pediatric Drops Or Syrups
4) By Ferric Hydroxide: Intravenous Iron Therapy; Ferric Hydroxide Polymaltose Complex; Dialysis-Specific Iron Therapy; Hospital-Based Injectable Formulations
Key Companies Profiled: Sanofi SA; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Sun Pharmaceutical Industries Ltd; CSL Vifor AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi SA
- Fresenius SE & Co. KGaA
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd
- CSL Vifor AG
- Zydus Lifesciences Limited
- Alkem Laboratories Ltd.
- Luitpold Pharmaceuticals Inc.
- Covis Pharma GmbH
- Pharmacosmos Therapeutics Inc.
- AFT Pharmaceuticals Ltd.
- Rockwell Medical Inc.
- Akebia Therapeutics Inc.
- Otsuka Pharmaceutical Co Ltd
- AdvaCare Pharma USA LLC
- Apotex Inc.
- Ironic Biotech AB
- KYE Pharmaceuticals Inc.
- Emcure Pharmaceuticals Limited
- Shield Therapeutics plc.